久久久无码视频,影音先锋女人av噜噜色,久久久久无码国产精品Sm高潮,人人色综合

首頁 > 產(chǎn)品目錄 > 信號通路 > Metabolism （代謝） > Acyltransferase > PF-04620110

PF-04620110

ChemLeader 98+%

trans-4-[4-(4-Amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]-cyclohexaneacetic acid

產(chǎn)品編號：CL2505 CAS No.：1109276-89-2 MDLNo： 分子式：C21H24N4O4 分子量：396.44
規(guī)格 庫存 目錄價 會員專享價 數(shù)量
5 mg 3-5days ￥550.00 登錄后可見
- +
10 mg 3-5days ￥800.00 登錄后可見
- +
25 mg 3-5days ￥1460.00 登錄后可見
- +

化學(xué)品安全說明書(MSDS)

下載MSDS
  • 基本信息
  • 相關(guān)文檔
  • 產(chǎn)品詳情
  • 相關(guān)文獻(xiàn)
基本信息
英文名稱 trans-4-[4-(4-Amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]-cyclohexaneacetic acid
中文名稱PF-04620110
CAS號1109276-89-2
分子式C21H24N4O4
分子量396.44
外觀White to off-white powder
儲存條件Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
產(chǎn)品詳情

PF-04620110 (PF04620110; PF 04620110) is a novel, potent, orally bioactive, and selective diglyceride acyltransferase-1 (DGAT1) inhibitor with the potential to treat type 2 diabetes mellitus. It inhibits DGAT1 with an IC50 of 19 nM. PF-04620110 has been advanced to clinical trials on the basis of the excellent pharmacologic and pharmacokinetic profiles. F-04620110 shows high selectivity versus a broad panel of off-target pharmacologic end points. In vivo DGAT-1 inhibition has been demonstrated through reduction of plasma triglyceride levels in rodents at doses of ≥0.1 mg/kg following a lipid challenge.

相關(guān)文獻(xiàn)
抱歉，暫時沒有相關(guān)文獻(xiàn)
相關(guān)產(chǎn)品
抱歉，暫時沒有相關(guān)產(chǎn)品
在線客服
小德
021-58180488
小立
021-58180488
在線服務(wù)時間: 工作日 9:00-18:00